Sign in
Not yet recruitingNo phase

Software and AI to check blocked blood flow during uterine fibroid treatment

Tests software that measures blood flow during uterine fibroid embolization procedures.

Key facts

Who runs it
Emanuele Barabino
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Artificial Intelligence for the Intra-procedural Assessment of Uterine Artery Embolization
Status
Not yet recruiting
People taking part
250 people, planned
Started
1 Dec 2025
Expected to end
31 May 2027
Type of study
Observational
Record updated
19 November 2025

Who can take part

The trial is looking for women with uterine fibroids that cause symptoms, who had uterine artery embolization (UAE). UAE is a procedure that blocks the blood supply to the fibroids.

Age
18 to 55 years
Sex
Female only
Disease stage
Uterine fibroids that cause symptoms, for example bleeding, pressure from their size, or pain.
Earlier treatment
People must have had UAE as their main, final treatment for the fibroids.
Main reasons for not taking part
  • No clinical follow-up after the procedure
  • Poor quality or incomplete images of the blood vessels (angiographic images)
  • For the past-data group: no baseline clinical or imaging data available
  • For the new-patient group: not able to give informed consent
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Female patients ≥18 years
  • Symptomatic uterine fibroids (e.g., bleeding, bulk symptoms, pain)
  • Underwent UAE as definitive therapy
  • Availability of baseline clinical/imaging data (for retrospective arm) or ability to provide informed consent (for prospective arm)

Who cannot take part

  • Lack of clinical follow-up
  • Poor quality or incomplete angiographic images

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Uterine fibroids

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Uterine artery embolization is a minimally invasive treatment for symptomatic uterine fibroids, but intra-procedural assessment of embolization adequacy currently relies on subjective angiographic criteria. This study evaluates a proprietary angiographic analysis software (AQ-VERO) that extracts quantitative time-to-density perfusion metrics in real time. The study aims to (1) validate the accuracy and reproducibility of AQ-VERO during uterine artery mebolization, and (2) develop an AI-based decision support system using AQ-VERO-derived metrics to improve objective intra-procedural assessment of treatment endpoints.

The group in the trial

  • 250 patients with a diagnosis of uterine fibroids who underwent uterine artery embolization

    Women diagnosed with symptomatic uterine fibroids who underwent image-guided uterine artery embolization as treatment. No additional surgical or medical interventions were performed during the procedure.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Validation and Implementation With Artificial Intelligence of Software for the Intra-procedural Assessment of Uterine Artery EMBOlization
Plain-language title
Software and AI to check blocked blood flow during uterine fibroid treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07230444, who can take part
Record updated
19 November 2025